Noxopharm Ltd (ASX:NOX)'s Graham Kelly tells Proactive they're planning to expand its NOXCOVID clinical program after receiving positive preliminary top-line data from its Phase 1 clinical trial for patients with coronavirus. The company's positioning Veyonda (idronoxil) as an anti-inflammatory drug in COVID-19 patients with moderate disease intended to stop progression to severe disease.
Noxopharm to expand NOXCOVID program following positive phase 1 results
